.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Cipla
Cantor Fitzgerald
Healthtrust
Citi
Express Scripts
Novartis
Medtronic
Mallinckrodt
Moodys

Generated: July 26, 2017

DrugPatentWatch Database Preview

Arbor Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for ARBOR PHARMS LLC, and when can generic versions of ARBOR PHARMS LLC drugs launch?

ARBOR PHARMS LLC has twenty-one approved drugs.

There are eighteen US patents protecting ARBOR PHARMS LLC drugs.

There are two hundred and sixty-five patent family members on ARBOR PHARMS LLC drugs in forty-two countries.

Summary for Applicant: Arbor Pharms Llc

Patents:18
Tradenames:22
Ingredients:14
NDAs:21
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Arbor Pharms Llc
ERY-TAB
erythromycin
TABLET, DELAYED RELEASE;ORAL062298-001Approved Prior to Jan 1, 1982RXNoNo► Subscribe► Subscribe► Subscribe
Arbor Pharms Llc
EDARBYCLOR
azilsartan kamedoxomil; chlorthalidone
TABLET;ORAL202331-002Dec 20, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Arbor Pharms Llc
SKLICE
ivermectin
LOTION;TOPICAL202736-001Feb 7, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Arbor Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Arbor Pharms Llc
GLIADEL
carmustine
IMPLANT;INTRACRANIAL020637-001Sep 23, 1996► Subscribe► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms Llc
EDARBYCLOR
azilsartan kamedoxomil; chlorthalidone
TABLET;ORAL202331-002Dec 20, 2011► Subscribe► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-002Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Arbor Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,790,708Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
8,906,412GABA analog prodrug sustained release oral dosage forms► Subscribe
6,833,140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity► Subscribe
7,186,855Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
9,238,616Prodrugs of gaba analogs, compositions and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Arbor Pharms Llc Drugs

Country Document Number Estimated Expiration
Japan4913796► Subscribe
Spain2416032► Subscribe
China102164918► Subscribe
China102429882► Subscribe
Russian Federation2006112549► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Arbor Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0034France► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/735/001 20111207
C/GB12/028United Kingdom► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
0120004 00052Estonia► SubscribePRODUCT NAME: EDARBI - ASILSARTAANMEDOKSOMIIL;REG NO/DATE: C(2011) 9280 FINAL 07.12.2011
/2015Austria► SubscribePRODUCT NAME: IVERMECTIN; NAT. REGISTRATION NO/DATE: 136170 20150602; FIRST REGISTRATION: MT MA 117/01101 20150402
2015000079Germany► SubscribePRODUCT NAME: IVERMECTIN ZU SEINER VERWENDUNG FUER DIE BEHANDLUNG VON ROSAZEA; NAT. REGISTRATION NO/DATE: 92429.00.00 20150429; FIRST REGISTRATION: MALTA MA 117/01101 20150402
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Argus Health
Colorcon
McKesson
Boehringer Ingelheim
Queensland Health
Farmers Insurance
Fish and Richardson
Accenture
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot